Cylene Pharmaceuticals ceased operation in 2013. It was a clinical stage private company designing and developing small molecule drugs against newly validated cancer targets. Cylene’s leadership in exploiting CK2 pathways enabled rational drug combinations for improved treatment outcomes against many cancer indications. The Company’s Pol I program provided a non-genotoxic mechanism for activating p53 to kill cancer cells.
Company Details
- Founded
- -
- in****@****rma.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- cylenepharma.com
- Keywords
- IT Consulting.
Cylene Pharmaceuticals Questions
Cylene Pharmaceuticals's website is cylenepharma.com
Cylene Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/cylene-pharmaceuticals
Cylene Pharmaceuticals's industry is
Biotechnology Research
Cylene Pharmaceuticals's top competitors are
Pimera Therapeutics,
Tildenbio,
Newfund,
Nosis Bio,
The Data Republic (Acquired By Kantar),
Best + Well,
Vildin,
Aepeg,
Arj Pharmaceuticals Llc,
Mullan Pharmaceutical Inc..
Cylene Pharmaceuticals's support email address is info@cylenepharma.com
Cylene Pharmaceuticals's categories are Biotechnology Research
Cylene Pharmaceuticals's founding year is 2001
